QTZM · Quantumzyme Corp.

IP Title Clarification via Confirmatory Assignment

This Amendment No. 2 directly addresses a critical vulnerability flagged in prior risk disclosures: the pending US20250146029A1 patent application, stemming from the February 21, 2023 Asset Purchase Agreement, was originally filed in the CEO's individual name without formal assignment to Quantumzyme Corp. (QTZM). To rectify this, the Company executed a confirmatory assignment agreement with CEO Kulkarni, explicitly transferring all rights, title, and interest to QTZM upon patent issuance. This proactive step—updating Items 1 (Business), 1A (Risk Factors), and 13 (Principal Executive Officers)—eliminates a key IP enforceability risk, ensuring the ibuprofen-degrading enzyme technology aligns with corporate ownership. Without this, potential disputes or third-party challenges could have derailed commercialization efforts, especially given the Company's heavy reliance on this single asset.

Prior Amendment Context

Building on Amendment No. 1, which refined FY2024 executive compensation disclosures, this filing reinforces QTZM's commitment to transparent governance. As a microcap development-stage biotech with dual-class voting structure (Series A/B Preferred shares concentrating control among insiders), such clarifications mitigate misalignment risks between insiders and common shareholders. Investors should view this as evidence of audit-driven diligence, preventing escalation of going-concern qualifiers tied to unresolved IP or compensation irregularities.

Business Model and Ibuprofen Enzyme Focus

QTZM's value proposition centers on a proprietary enzyme for ibuprofen degradation, targeting environmental and regulatory pain points in pharmaceutical waste management. Sourced via the 2023 asset purchase, this IP underpins scalability from lab validation to industrial application. However, as a one-employee entity lacking equipment, real property, or revenue, execution hinges on patent grant, CEO retention, and external funding—none of which this amendment alters but all of which it bolsters through clearer title.

Heightened Execution and IP Risks

Updated Risk Factors amplify QTZM's speculative profile: total dependence on CEO Kulkarni for technical expertise, absence of binding third-party alliances for scale-up, and vulnerabilities like prosecution costs or grant denial. Regulatory gauntlets (FDA GRAS status, EPA TSCA compliance) loom large, alongside competition from established players like Novozymes and Codexis. With no balance sheet impact from IP formalization and persistent capital needs for validation phases, success pivots on strategic partnerships and dilution-tolerant financing. This filing signals governance maturity but underscores why QTZM remains a high-risk, binary-outcome play for patient investors.